About Neuraltus

Driven to Improve the Lives of People Living with Neurodegenerative Diseases

Neuraltus Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to the development of therapeutics to treat neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease as well as inherited metaboloic disorders such as Fabry's disease and Gaucher's disease which also result in neuronal cell death.

Every Neuraltus employee is dedicated to advancing therapies that have the potential to make a difference in the lives of people living with these often devastating neurological conditions. We combine world-class scientific expertise, a strong patent portfolio and an unshakeable commitment to working with the patient community to develop innovative treatments. Neuraltus is configured as a “virtual” drug development organization.  We have a small internal team and a network of experienced advisors and service providers to advance our development programs.

Neuraltus began operations in 2004 based on a broad technology portfolio and intellectual property assembled by the company founders. Neuraltus has received $45 million in financing from leading venture groups, including Latterell Venture Partners and VantagePoint Capital Partners, to support its research and drug development efforts.

Our lead product, NP001, is in clinical development for the treatment of ALS, also known as Lou Gehrig’s disease.

ALS is a fatal neurodegenerative disease characterized by degeneration of motor neurons in the spinal cord and brain. The cause of the disease is currently unknown, but there is increasing evidence that associates neuroinflammation with the progression of the disease. It is believed that in people with ALS, there are increased levels of inflammatory or activated macrophages. Macrophages are a type of white blood cell that, in response to certain triggers in certain diseases, become activated and be found in certain tissues of the body. When in an activated state, they release a number of compounds that result in inflammation and lead to motor neuron damage and death. NP001, a regulator of macrophage activation, converts these activated inflammatory macrophages back to their normal, non-inflammatory state. Neuraltus is currently seeking funding to proceed with additional clinical studies of NP001 that will inform future pivotal studies that could potentially be the basis for regulatory submissions for marketing approval.

As we work to advance the NP001 clinical program, we actively seek input from patient advocacy organizations with expertise about the challenges facing ALS patients. We are committed to keeping the ALS community informed of our progress and to becoming a trusted partner to those affected by the disease.